- Home
-
Product Finder
- Arixtra®▼ (Fondaparinux sodium)
- Arzerra®▼ (ofatumumab)
- Atriance® (nelarabine)
- Avamys®▼ (Fluticasone Furoate)
- Avodart® (dutasteride)
- Benlysta®▼ (belimumab)
- Combodart™▼ (0.5 mg dutasteride / 0.4 mg tamsulosin hydrochloride)
- Duodart™▼ (0.5 mg dutasteride / 0.4 mg tamsulosin hydrochloride)
- Hycamtin®▼ (topotecan)
- ReQuip®LP (ropinirole hydrochloride prolonged-release tablets)
- ReQuip® PD (ropinirole hydrochloride prolonged-release tablets)
- ReQuip®XL (ropinirole hydrochloride prolonged-release tablets)
- ReQuip Depot® (ropinirole hydrochloride prolonged-release tablets)
- ReQuip Modutab™ (ropinirole hydrochloride prolonged-release tablets)
- ReQuip Prolib™ and ReQuip® prolonged-release tablets (ropinirole hydrochloride prolonged-release tablets)
- Revolade®▼ (eltrombopag)
- Seretide® (salmeterol xinafoate/fluticasone propionate)
- Trobalt™▼ (Retigabine)
- Tyverb®▼ (lapatinib)
- Viani® (salmeterol xinafoate/fluticasone propionate)
- Votrient®▼ (pazopanib)
- belimumab (Benlysta®▼)
- dutasteride (Avodart®)
- eltrombopag (Revolade®▼)
- Fondaparinux sodium (Arixtra®▼)
- Fluticasone Furoate (Avamys®▼)
- lapatinib (Tyverb®▼)
- nelarabine (Atriance®)
- ofatumumab (Arzerra®▼)
- pazopanib (Votrient™▼)
- ropinirole hydrochloride prolonged-release tablets (ReQuip Modutab™, also known as ReQuip®LP, ReQuip® PD, ReQuip®XL, ReQuip Depot®, ReQuip Prolib™ and ReQuip® prolonged-release tablets)
- Retigabine (Trobalt™▼)
- salmeterol xinafoate/fluticasone propionate (Seretide®, also known as Viani®)
- topotecan (Hycamtin®▼)
- Therapy Areas
- News
- Media and Resources
Product Finder
Browse the product finder by:
GSK Product Name
Generic Product Name
Medical Indication
-
All Medical Indications
- Benlysta®▼ (belimumab)
- Votrient™▼ (pazopanib)
-
Allergic Rhinitis
- Avamys®▼ (Fluticasone Furoate)
-
Asthma
-
Benign Prostatic Hyperplasia
- Avodart® (dutasteride)
- Duodart™▼, also known as Combodart™▼ (0.5 mg dutasteride / 0.4 mg tamsulosin hydrochloride)
-
Breast Cancer
- Tyverb®▼ (lapatinib)
-
COPD
-
Cardiology
- Arixtra®▼ (Fondaparinux sodium)
-
Cervical Cancer
- Hycamtin®▼ (topotecan)
-
Chronic Lymphocytic Leukaemia
- Arzerra®▼ (ofatumumab)
-
Epilepsy
- Trobalt™▼ (Retigabine)
-
Haematology
- Atriance® (nelarabine)
- Revolade®▼ (eltrombopag)
-
Leukaemia
- Atriance® (nelarabine)
-
Lung Cancer
- Hycamtin®▼ (topotecan)
-
Lymphoma
- Atriance® (nelarabine)
-
Neurology
- ReQuip Modutab™, also known as ReQuip®LP, ReQuip® PD, ReQuip®XL, ReQuip Depot®, ReQuip Prolib™ and ReQuip® prolonged-release tablets (ropinirole hydrochloride prolonged-release tablets)
-
Ovarian Cancer
- Hycamtin®▼ (topotecan)
-
Parkinson's Disease
- ReQuip Modutab™, also known as ReQuip®LP, ReQuip® PD, ReQuip®XL, ReQuip Depot®, ReQuip Prolib™ and ReQuip® prolonged-release tablets (ropinirole hydrochloride prolonged-release tablets)
Therapy Areas
-
All Therapy Areas
- Benlysta®▼ (belimumab)
-
Cardiovascular
- Arixtra®▼ (Fondaparinux sodium)
-
Neurology
- ReQuip Modutab™, also known as ReQuip®LP, ReQuip® PD, ReQuip®XL, ReQuip Depot®, ReQuip Prolib™ and ReQuip® prolonged-release tablets (ropinirole hydrochloride prolonged-release tablets)
- Trobalt™▼ (Retigabine)
-
Oncology
- Arzerra®▼ (ofatumumab)
- Atriance® (nelarabine)
- Hycamtin®▼ (topotecan)
- Revolade®▼ (eltrombopag)
- Tyverb®▼ (lapatinib)
- Votrient™▼ (pazopanib)
-
Respiratory and Allergy
-
Urology
- Avodart® (dutasteride)
- Duodart™▼, also known as Combodart™▼ (0.5 mg dutasteride / 0.4 mg tamsulosin hydrochloride)
Other Products
Content is provided on this website for products with a centralised European product licence. In some cases, content may be provided relating to products that have mutual recognition or national licence, which has been created for European audiences.
It may be that the product you are searching for has a national product licence, not a European product licence. Please refer to your local GSK offices for more information on GSK products that are available in your country.